biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Consequences of a "no" vote: from IR

<< Previous

Bullboard Posts

Next >>

Comment by OttawaPeteron Jan 20, 2023 3:20pm

82 Views

Post# 35236312

RE:RE:RE:RE:RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR

prophetoffactz wrote: "Md got a heck of a lot more done than DR"

Incredibly hard to argue that.

Rathjen's Chiesi deal beats Day's Prothena deal.

Rathjen delivered more deals and evaluations(Chiesi, J&J, Neuramedy, Daiichi, Oxyrane, Aposense, and potentially Ellipses) than Day(Prothena, undisclosed major pharma).

Rathjen dellvered more transformational deals(Cresence, Biodexa).

Day failed to advance xB3 into the clinic as Rathjen, and put BTI in a financial mess as Rathjen but atleast Rathjen has the balls to address the disaster and put the company on a viable path with the Biodexa deal and potential US$20 million in financing. Rathjen may finally get BTI on NASDAQ too which Day failed to do. Biodexa also significantly strengthens BTI with scale, resources, and complementary assets. Biodexa could have the backing on important fund like Armistice Capital as a major shareholder. Day didn't deliver one major backer like this. If Day had the force of character to correct BTI's course as Rathjen is now demonstrating BTI could be in a much healthier place today.

P.S. POF's shadow is reflecting in the lake & the once again paid shill clearly swallowed a bitter pill.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market